CLNN vs. GLSI, LFCR, ABEO, ALIM, RIGL, VERU, SGMT, CNTX, RNAC, and PRQR
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include Greenwich LifeSciences (GLSI), Lifecore Biomedical (LFCR), Abeona Therapeutics (ABEO), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Veru (VERU), Sagimet Biosciences (SGMT), Context Therapeutics (CNTX), Cartesian Therapeutics (RNAC), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical preparations" industry.
Greenwich LifeSciences (NASDAQ:GLSI) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.
In the previous week, Greenwich LifeSciences had 8 more articles in the media than Clene. MarketBeat recorded 17 mentions for Greenwich LifeSciences and 9 mentions for Clene. Clene's average media sentiment score of 1.08 beat Greenwich LifeSciences' score of 0.48 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 52.9% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 25.1% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Greenwich LifeSciences currently has a consensus price target of $36.00, indicating a potential upside of 172.93%. Clene has a consensus price target of $6.50, indicating a potential upside of 1,812.33%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Clene is more favorable than Greenwich LifeSciences.
Greenwich LifeSciences has a net margin of 0.00% compared to Greenwich LifeSciences' net margin of -7,873.23%. Clene's return on equity of -117.99% beat Greenwich LifeSciences' return on equity.
Greenwich LifeSciences has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
Greenwich LifeSciences has higher earnings, but lower revenue than Clene. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
Clene received 54 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 75.95% of users gave Clene an outperform vote while only 37.50% of users gave Greenwich LifeSciences an outperform vote.
Summary
Clene beats Greenwich LifeSciences on 9 of the 16 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
